CA
BDTX icon

CHI Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

CHI Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$2.07M Sell
720,000
-30,000
-4% -$111K 0.82% 21
2023
Q2 		$3.79M Buy
+750,000
New +$1.53M 1.15% 17

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CHI Advisors's BDTX Position: Q3 2023 in Review

CHI Advisors reduced its Black Diamond Therapeutics (BDTX) stake by 4% in Q3 2023, selling an estimated $111K and leaving 720,000 shares worth $2.07M. The position accounts for 0.82% of the portfolio, ranked #21.

CHI Advisors first reported a position in BDTX in Q2 2023 and has held it in 2 quarters since. The position peaked at $3.79M in Q2 2023. 73 funds tracked by Wall St. Rank hold BDTX as of Q3 2023.

  • CHI Advisors held 720,000 shares of Black Diamond Therapeutics worth $2.07M as of Q3 2023.
  • CHI Advisors sold 30,000 Black Diamond Therapeutics shares in Q3 2023, an estimated $111K.
  • Black Diamond Therapeutics made up 0.82% of CHI Advisors's portfolio in Q3 2023, its #21 holding.
  • CHI Advisors first reported a position in Black Diamond Therapeutics in Q2 2023 and has held it in 2 quarters since.
  • CHI Advisors's Black Diamond Therapeutics position peaked at $3.79M in Q2 2023.
  • 73 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.